Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants

Abstract Background Most borderline ovarian tumors (BOTs) are cured with surgery. However BOTs with invasive implants have a poor prognosis with a mortality of 20–40%. The benefit of adjuvant chemotherapy (CT) in this setting remains poorly defined. Methods Retrospective study of serous BOT + invasi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2014-01, Vol.132 (1), p.23-27
Hauptverfasser:	Leary, Alexandra, Petrella, Marie Christina, Pautier, Patricia, Duvillard, Pierre, Uzan, Catherine, Tazi, Youssef, Ledoux, Florence, Gouy, Sébastien, Morice, Philippe, Lhommé, Catherine
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant chemotherapy Adolescent Adult Aged Antineoplastic Agents - therapeutic use Chemotherapy, Adjuvant Cystadenocarcinoma, Serous - drug therapy Cystadenocarcinoma, Serous - mortality Cystadenocarcinoma, Serous - pathology Female Hematology, Oncology and Palliative Medicine Humans Invasive implants Middle Aged Neoplasm Staging Obstetrics and Gynecology Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality Ovarian Neoplasms - pathology Platinum - therapeutic use Retrospective Studies Serous borderline ovarian tumor Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!